Log in

NASDAQ:VBIVVBI Vaccines Stock Price, Forecast & News

$2.87
-0.07 (-2.38 %)
(As of 07/3/2020 04:00 PM ET)
Add
Compare
Today's Range
$2.83
Now: $2.87
$3.00
50-Day Range
$1.89
MA: $2.43
$3.13
52-Week Range
$0.47
Now: $2.87
$3.50
Volume4.48 million shs
Average Volume10.67 million shs
Market Capitalization$661.97 million
P/E RatioN/A
Dividend YieldN/A
Beta1.74
VBI Vaccines Inc., a biopharmaceutical company, develops and sells vaccines to address unmet needs in infectious disease and immuno-oncology in Israel and internationally. The company offers Sci-B-Vac, a prophylactic hepatitis B vaccine for adults, children, and newborns; and eVLP, a vaccine platform for the design of enveloped virus-like particle vaccines that closely mimic the structure of the target virus. It is also developing cytomegalovirus vaccine candidate for infectious disease; and glioblastoma multiforme vaccine candidate for immuno-oncology. The company was formerly known as SciVac Therapeutics Inc. and changed its name to VBI Vaccines Inc. in May 2016. The company is headquartered in Cambridge, Massachusetts.
Read More
VBI Vaccines logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 3.3Dividend Strength: 0.0Insider Behavior: 3.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.96 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:VBIV
CUSIPN/A
Phone617-830-3031

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$2.22 million
Book Value$0.50 per share

Profitability

Net Income$-54,810,000.00
Net Margins-2,133.79%

Miscellaneous

Employees108
Market Cap$661.97 million
Next Earnings Date8/14/2020 (Estimated)
OptionableOptionable

Receive VBIV News and Ratings via Email

Sign-up to receive the latest news and ratings for VBIV and its competitors with MarketBeat's FREE daily newsletter.

VBI Vaccines (NASDAQ:VBIV) Frequently Asked Questions

How has VBI Vaccines' stock been impacted by COVID-19 (Coronavirus)?

VBI Vaccines' stock was trading at $0.9171 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, VBIV shares have increased by 212.9% and is now trading at $2.87. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of VBI Vaccines?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for VBI Vaccines in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for VBI Vaccines.

When is VBI Vaccines' next earnings date?

VBI Vaccines is scheduled to release its next quarterly earnings announcement on Friday, August 14th 2020. View our earnings forecast for VBI Vaccines.

How were VBI Vaccines' earnings last quarter?

VBI Vaccines Inc (NASDAQ:VBIV) posted its earnings results on Wednesday, May, 6th. The biopharmaceutical company reported ($0.05) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.06) by $0.01. The biopharmaceutical company earned $0.42 million during the quarter, compared to the consensus estimate of $0.83 million. VBI Vaccines had a negative return on equity of 57.79% and a negative net margin of 2,133.79%. View VBI Vaccines' earnings history.

What price target have analysts set for VBIV?

4 brokers have issued 12-month target prices for VBI Vaccines' stock. Their forecasts range from $3.00 to $8.00. On average, they expect VBI Vaccines' share price to reach $4.75 in the next year. This suggests a possible upside of 65.5% from the stock's current price. View analysts' price targets for VBI Vaccines.

Has VBI Vaccines been receiving favorable news coverage?

Media headlines about VBIV stock have trended negative recently, InfoTrie Sentiment reports. InfoTrie identifies positive and negative press coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. VBI Vaccines earned a media sentiment score of -2.4 on InfoTrie's scale. They also assigned news coverage about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the stock's share price in the next several days. View the latest news about VBI Vaccines.

Who are some of VBI Vaccines' key competitors?

What other stocks do shareholders of VBI Vaccines own?

Based on aggregate information from My MarketBeat watchlists, some companies that other VBI Vaccines investors own include Canaccord Genuity (), BMO Capital Markets (), Stifel Nicolaus (), Wunderlich (), Standpoint Research (), Duncan Williams (), Soleil Securities (), Sterne Agee CRT (), Robert W. Baird () and Wellington Shields ().

Who are VBI Vaccines' key executives?

VBI Vaccines' management team includes the following people:
  • Mr. Jeff R. Baxter, CEO, Pres & Director (Age 58)
  • Dr. David Evander Anderson, Chief Scientific Officer (Age 49)
  • Dr. Francisco Diaz-Mitoma, Chief Medical Officer (Age 64)
  • Mr. Christopher McNulty, CFO & Head of Bus. Devel. (Age 42)
  • Ms. Athena Kartsaklis, Sr. VP of Fin., Chief Compliance Officer & Principal Financial Officer (Age 54)

What is VBI Vaccines' stock symbol?

VBI Vaccines trades on the NASDAQ under the ticker symbol "VBIV."

How do I buy shares of VBI Vaccines?

Shares of VBIV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is VBI Vaccines' stock price today?

One share of VBIV stock can currently be purchased for approximately $2.87.

How big of a company is VBI Vaccines?

VBI Vaccines has a market capitalization of $661.97 million and generates $2.22 million in revenue each year. The biopharmaceutical company earns $-54,810,000.00 in net income (profit) each year or ($0.46) on an earnings per share basis. VBI Vaccines employs 108 workers across the globe.

What is VBI Vaccines' official website?

The official website for VBI Vaccines is www.vbivaccines.com.

How can I contact VBI Vaccines?

VBI Vaccines' mailing address is 222 Third Street Suite 2241, Cambridge MA, 02142. The biopharmaceutical company can be reached via phone at 617-830-3031 or via email at [email protected]

This page was last updated on 7/4/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.